 eFitnessNow [1] |
NewDiabetesDrug Faces Delay, FDA Extends Review Period [1]
Attorney at Law The Food and Drug Administration has delayed making a decision on whether to approve a newType 2 diabetesdrug proposed by Bristol Myers-Squibb Co. and AstraZeneca PLC. The drug, saxagliptin, would be sold under the brand name Onglyza.… astrazeneca: FDA Extends Timeline For Onglyza NDA To July 30 [1] FDA extends timeline to approvediabetesdrug of Bristol-Myers… [2] FDA extended time to review saxagliptin for treatment ofdiabetes [3] |